Investment Thesis
AEON Biopharma exhibits severe financial distress with negative stockholders' equity of -$19.9M, indicating the company is technically insolvent. The company is pre-revenue or near-zero revenue with substantial operating losses (-$7.3M) and negative free cash flow (-$12.6M), demonstrating unsustainable burn rate with only $5.9M in cash reserves.
AEON Strengths
- Maintains $5.9M in cash equivalents providing short-term operational runway
- Early-stage pharmaceutical company with potential pipeline assets (typical for sector)
- Recent insider activity suggests management involvement in strategic decisions
AEON Risks
- Negative stockholders' equity indicates technical insolvency and existential viability concerns
- Liabilities ($28.6M) exceed assets ($8.7M) by $19.9M with negative working capital
- Negative operating cash flow of -$12.6M and absence of revenue creates unsustainable burn with ~5 months of cash runway
- No revenue generation suggests pre-commercial or failed commercialization stage
- Negative ROA of -23.9% indicates severe asset utilization inefficiency
Key Metrics to Watch
- Cash runway and quarterly burn rate relative to remaining cash balance
- Path to revenue and clinical trial progress or regulatory milestones
- Changes in total liabilities and working capital position
- Operating cash flow trends and any clinical advancement announcements
AEON Financial Metrics
AEON Profitability Ratios
AEON Balance Sheet & Liquidity
AEON 5-Year Financial Trend
5-Year Trend Summary: AEON Biopharma, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.44 indicates the company is currently unprofitable.
AEON Growth Metrics (YoY)
AEON Capital Allocation
AEON SEC Filings
Access official SEC EDGAR filings for AEON Biopharma, Inc. (CIK: 0001837607)